« Previous
Next »
Archives of Medical Research
Volume 41, Issue 3
, Pages 151-153
, April 2010
Comparison of Bioartificial Pancreas Performance in the Bone Marrow Cavity and Intramuscular Space
References
- . Bioartificial pancreas for the treatment of diabetes. Cell Transpl. 2008;17:11–17
- Chitosan/gelatin hydrogel as immunoisolative matrix for injectable bioartificial pancreas. Xenotransplantation. 2008;15:407–416
- Macrophage overgrowth affects neighboring nonovergrown encapsulated islets. J Surg Res. 2003;115:235–241
- . Causes of limited survival of microencapsulated pancreatic islet grafts. J Surg Res. 2004;121:141–150
- . The bone marrow as a potential receptor site for pancreatic islet grafts. Arch Med Res. 2008;39:139–144
- In vitro study of using calcium phosphate cement as immunoisolative device to enclose insulinoma/agarose microspheres as bioartificial pancreas. Biotechnol Bioeng. 2007;98:1288–1295
- Preparation of β-TCP/HAP biphasic ceramics with natural bone structure by heating bovine cancellous bone with the addition of (NH4)2HPO4. J Biomed Mater Res. 2000;51:157–163
- Calcium phosphate cement chamber as an immunoisolative device for bioartificial pancreas: In vitro and preliminary in vivo study. Pancreas. 2010;
- . Insulinoma. Best Pract Res Clin Gastroenterol. 2005;19:783–798
- Response of encapsulated rat pancreatic islets to hypoxia. Cell Transpl. 2003;12:867–875
- Islet grafting and imaging in a bioengineered intramuscular space. Transplantation. 2009;88:1065–1074
- Basal and glucagon-stimulated plasma C-peptide concentrations in healthy dogs, dogs with diabetes mellitus, and dogs with hyperadrenocorticism. J Vet Intern Med. 1997;10:116–122
- Oxygen saturation in the bone marrow of healthy volunteers. Blood. 2002;99:394
- Islet-cell-to-cell communication as basis for normal insulin secretion. Diabetes Obes Metab. 2007;S2:118–132
- Beta-cell crosstalk: a further dimension in the stimulus-secretion coupling of glucose-induced insulin release. Diabetes Metab. 2002;6(Pt 2):3S45–3S53
- C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop. Diabetes. 2004;53:250–264
PII: S0188-4409(10)00027-5
doi: 10.1016/j.arcmed.2010.03.002
© 2010 IMSS. All rights reserved.
« Previous
Next »
Archives of Medical Research
Volume 41, Issue 3
, Pages 151-153
, April 2010
